Subscribe or Manage Preferences

ACR Responds to 2019 Benefit and Payment Parameters Proposed Rule

Rheumatology Practice Management December 2017 Vol 5 No 6 - Health Policy
Rebecca Bailey

 

In a press release from November 28, 2017, the American College of Rheumatology (ACR) is urging the Centers for Medicare & Medicaid Services (CMS) to reconsider proposals reducing health exchange insurance coverage, affordability, and patient choice.

ACR officials said the response originates from the CMS 2019 Benefit and Payment Parameters proposed rule, which governs the state and federal health exchanges created by the Affordable Care Act.

“The ACR is committed to ensuring that Americans living with rheumatic diseases have access to high-value, high-quality healthcare. While we are pleased to see CMS is considering changes that would reduce drug costs and promote pricing transparency, we are deeply concerned about proposed changes that would make it more difficult for our patients to access and afford the care they need,” said ACR President David Daikh, MD, PhD.

Specifically, the organization opposes CMS’s proposal to permit states to select their own essential health benefit benchmark plans, maintaining the policy could create a “race to the bottom” wherein states will pursue the least acceptable coverage at the lowest cost, thereby restricting patient access to care. This flexibility may also result in states drastically limiting biologic drug coverage. Therefore, the ACR strongly recommended to the CMS that clinical decisions regarding treatments—especially those associated with medications—stay in the jurisdiction of providers. The rheumatology leaders stressed that treatment plans, as well as the authority to choose the use of one therapy over another, should not be determined by states or insurers.

The ACR also expressed serious concerns regarding CMS’s current plan to increase the rate review threshold from 10% to 15%, as this proposal would allow plans that have annual premium increases <15% to avoid the review process for unreasonable premium increases. The increase could result in more financial barriers for patients who are looking for affordable insurance coverage. Patients may also struggle to afford plan copayments and deductibles, because premium increases compound every year.

In addition, there are issues associated with the plan rate review designating Children’s Health Insurance Program’s buy-in programs as minimum essential coverage without first undergoing an application process. Because there is no guarantee that coverage under these programs would be equivalent, the ACR urged CMS to withdraw this proposal, or at least supply a reasoned analysis for the new standard and codify it into existing regulations.

“Adequate and affordable health insurance coverage is absolutely critical to managing chronic and complex rheumatic diseases and conditions,” Dr Daikh said. “We urge CMS to reconsider proposals that would severely reduce insurance coverage, access, and patient choice under the state and federal health exchanges. The ACR will continue to serve as a resource to CMS as it works to expand patient access to affordable care.”

Related Items
FDA Taking Steps to Promote Generic Drug Competition
Eileen Koutnik-Fotopoulos
Rheumatology Practice Management February 2018 Vol 6 No 1 published on February 16, 2018 in Health Policy
Medical Groups Applaud Congressional Leaders for Bipartisan Agreement to Repeal Medicare Therapy Caps
Anne Rowe
Rheumatology Practice Management December 2017 Vol 5 No 6 published on January 8, 2018 in Health Policy
FDA Under the Trump Administration: Can Scott Gottlieb Improve the Drug Approval Process?
Laura Morgan
Rheumatology Practice Management October 2017 Vol 5 No 5 published on October 20, 2017 in Health Policy
FDA Under the Trump Administration: Can Scott Gottlieb Improve the Drug Approval Process?
Laura Morgan
Urology Practice Management - Web Exclusives published on September 20, 2017 in Health Policy
Appeals Process for Challenging High-Stakes Claims
Mark Post, North Texas Joint Care Dallas, TX
Rheumatology Practice Management August 2017 Vol 5 No 4 published on August 16, 2017 in Health Policy
ACR Voices Opposition to Proposed Federal Program and Institution Budget Cuts
Sophie Granger
Rheumatology Practice Management June 2017 Vol 5 No 3 published on June 28, 2017 in Health Policy
Final Report by Institute for Clinical and Economic Review Raises Concerns in the Rheumatology Community
Rebecca Bailey
Rheumatology Practice Management June 2017 Vol 5 No 3 published on June 28, 2017 in Health Policy
Medical Groups Concerned That AHCA May Limit Access to Care
Leslie Wyatt
Rheumatology Practice Management April 2017 Vol 5 No 2 published on April 25, 2017 in Health Policy
ACR President Stresses Crucial Need for Rheumatologist Representation in AMA
Sophie Granger
Rheumatology Practice Management April 2017 Vol 5 No 2 published on April 25, 2017 in Health Policy
ACR Applauds 21st Century Cures Act, But Urges Congress to Dedicate Funds for Arthritis Research Program
Leslie Wyatt
Rheumatology Practice Management February 2017 Vol 5 No 1 published on March 2, 2017 in Health Policy
Last modified: February 23, 2018
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search